Antisense Therapeutics Ltd Company Profile
ASX:ANP

A Phase 2 Biotech Utilising Antisense Technology to Bring Life Changing Innovative Medicine to Patients in Need.

Antisense Therapeutics (ASX:ANP) is a Biotechnology company developing and commercializing antisense pharmaceuticals for large unmet markets in rare disease, specifically Duchenne muscular dystrophy (DMD).

  • Company
    Antisense Therapeutics Ltd
  • Website
  • Sector
    Pharmaceuticals
  • Industry
    Pharmaceuticals
  • Code
    ASX:ANP

Company Overview


Antisense Therapeutics Ltd (ASX:ANP) is an Australian publicly listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development.

The Company's flagship program is ATL1102 which primarily services the market of Duchene's Muscular Distrophy Disease (DMD) patients. Duchenne muscular dystrophy (DMD) is a rare and fatal genetic muscle wasting disease that affects boys. At current, ATL1102 is the only therapy in development for DMD targeting CD49d to slow disease progression by reducing inflammation and resultant muscle damage with potential application across a broad range of inflammatory diseases.

Share this profile:

With over 20 years of technology refinement, Antisense is a mature drug discovery and therapeutic platform.

With a growing need for new therapeutic approaches in the multi-billion-dollar DMD market, Antisense Therapeutics is looking to bring life changing innovative medicines to patients in need.
Positive Phase II trial Results

Open Label Phase II trial reported positive effects across multiple measures of muscle structure, function & strength. Data also suggested an overall ‘stabilsation’ in disease progression which in itself is a very positive clinical outcome.

Significant Market Opportunity

The global DMD drug market is estimated to reach US$4B by 2023 and US$10B by 2030.

Untapped Market Niche in DMD

ATL1102 is the only therapy in development for DMD targeting CD49d to slow disease progression by reducing inflammation and resultant muscle damage with potential application across a broad range of inflammatory diseases.

Latest Presentation

Click here to view Antisense Therapeutics' latest Presentation

ATL1102 - Strong Phase II Study Results

Open Label Phase II trial involved nine non-ambulant (wheelchair bound) boys 10-18 years of age with DMD conducted over 24 weeks of dosing. Key highlights from this trial were the confirmation of the drug’s safety and tolerability, statistical improvements across different measures of motor function & strength and activity on the targeted CD49d immune cells consistent with the drug’s proposed mechanism of action. MRI data also suggested a stabilization of the fat % in muscles and preservation of functional muscle mass.

What is Duchenne Muscular Dystrophy (DMD)?

Duchenne muscular dystrophy (DMD) is a devastating genetic muscular disease caused by loss of dystrophin with progressive muscle wasting & associated muscle injury leading to inflammation & fibrosis. DMD has a 100% Mortality rate for patients in their 30's. One of the most common fatal genetic disorders, DMD affects approximately one in every 3,500 to 5,000 males worldwide. A key challenge in the management of DMD patients is to reduce the inflammation that exacerbates the muscle fibre damage.

ATL1102 in the Global DMD Market

ATL1102 is well positioned for global success within a high-growth multi-billion-dollar DMD market. ATL1102’s differentiated mechanism of action has the potential to be synergistic with other marketed compounds and those in development for DMD allowing for higher levels of market penetration. Additionally, ATL1102 has the potential to be used across all DMD subtypes.

Technology Overview

View an in-depth overview of Antisense Technology

EU Phase IIb/III Study Program

A multicentre, randomised, double-blind, placebo-controlled study to assess the efficacy, safety , and pharmacokinetic profile of two dose levels of ATL1102 to be conducted in 108 (114 randomised) DMD non-ambulant participants in ~9 countries across >30 trial sites.

Directors & Management

The Antisense Therapeutics senior management team have a highly complimentary skill set and a track record of successfully commercialising biopharmaceutical products on the international stage.
Profile image
Mr Mark Diamond
Managing Director & CEO
Profile image
Dr Charmaine Gittleson
Chairperson
Profile image
Mr Phillip Hains
Chief Financial Officer
Clock icon Information current at 18 November 2021

Company Videos

2 Videos

News Coverage

Current news mentioning Antisense Therapeutics Ltd from top publishers around the web.
Powered by  

How do I invest?

Considering investing in Antisense Therapeutics Ltd?
Here's how to get started.
Low Cost Brokerage ASX Cheapest ASX Trading Platform
  1. 1

    Create account

    Open an account with an online broker of your choice. If you do not have an existing broker, consider Vested Equities' A$9.50 flat fee platform.

    Sign up now »
  2. 2

    Search for ASX:ANP

    On your online investment platform search for the stock ticker code ASX:ANP to bring up the company's shares.

  3. 3

    Buy shares

    Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.

Up